Processa Pharmaceuticals Inc Cash Flow Conversion Efficiency
Processa Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Processa Pharmaceuticals Inc (PCSA) has a cash flow conversion efficiency ratio of -1.413x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.59 Million) by net assets ($2.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Processa Pharmaceuticals Inc (2011–2025)
Cash flow conversion efficiency of Processa Pharmaceuticals Inc from 2011 to 2025. This chart illustrates how Processa Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Processa Pharmaceuticals Inc (PCSA) stock price for real-time trading data and today's change.
Processa Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Processa Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Processa Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Processa Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see PCSA company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VinaCapital Vietnam Opportunity Fund
LSE:VOF
|
0.029x |
|
Clever Group Corp
VN:ADG
|
N/A |
|
Da Lue International Holding Co Ltd
TWO:4804
|
0.027x |
|
Greentech Metals Ltd
AU:GRE
|
-0.056x |
|
Trend Gayrimenkul Yatirim Ortakligi AS
IS:TDGYO
|
0.033x |
|
Antelope Enterprise Holdings Ltd
NASDAQ:AEHL
|
0.191x |
|
TPI Composites Inc
NASDAQ:TPIC
|
0.054x |
|
Sky Energy Indonesia Tbk PT
JK:JSKY
|
1.424x |
Annual Cash Flow Conversion Efficiency for Processa Pharmaceuticals Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Processa Pharmaceuticals Inc from 2011 to 2025. Review PCSA FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.58 Million | $-11.39 Million | -2.041x | +69.21% |
| 2024-12-31 | $1.70 Million | $-11.25 Million | -6.630x | -310.21% |
| 2023-12-31 | $4.99 Million | $-8.06 Million | -1.616x | -25.70% |
| 2022-12-31 | $7.47 Million | $-9.61 Million | -1.286x | -275.88% |
| 2021-12-31 | $25.49 Million | $-8.72 Million | -0.342x | -149.64% |
| 2020-12-31 | $22.94 Million | $-3.14 Million | -0.137x | +60.08% |
| 2019-12-31 | $8.01 Million | $-2.75 Million | -0.343x | +10.20% |
| 2018-12-31 | $9.70 Million | $-3.71 Million | -0.382x | +91.38% |
| 2017-12-31 | $373.16K | $-1.65 Million | -4.434x | -1106.31% |
| 2016-12-31 | $-1.98 Million | $-871.91K | 0.441x | 0.00% |
| 2015-12-31 | $-1.98 Million | $-871.91K | 0.441x | +119.75% |
| 2014-12-31 | $1.21 Million | $-2.70 Million | -2.231x | -46.86% |
| 2013-12-31 | $1.67 Million | $-2.54 Million | -1.519x | -106.37% |
| 2012-12-31 | $2.56 Million | $-1.89 Million | -0.736x | -187.76% |
| 2011-12-31 | $2.78 Million | $-710.00K | -0.256x | -- |
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer ce… Read more